HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment

PURPOSE: Constituting 15 to 20% of breast cancer cases, the triple-negative subtype lacks effective treatments as being less responsive to hormone-associated therapies. Alternatively, a more powerful immunotherapeutic vaccination can trigger immune recognition and destruction against breast cancer b...

Descripción completa

Detalles Bibliográficos
Autor principal: Zhou, Yihan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356871/
https://www.ncbi.nlm.nih.gov/pubmed/36692548
http://dx.doi.org/10.1007/s00432-023-04574-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356871/
https://www.ncbi.nlm.nih.gov/pubmed/36692548
http://dx.doi.org/10.1007/s00432-023-04574-9

Ejemplares similares